Price T Rowe Associates Inc Cti Biopharma Corp Transaction History

Price T Rowe Associates Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $4,746 - $6,791	1,130 Added 3.01%	38,723 $163,000
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $7,360 - $10,205	1,654 Added 4.6%	37,593 $226,000
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $36,984 - $51,267	6,900 Added 23.76%	35,939 $210,000
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $5,818 - $10,276	1,639 Added 5.98%	29,039 $173,000
Q1 2022 May 16, 2022	SELL	$1.9 - $5.23 $10,070 - $27,719	-5,300 Reduced 16.21%	27,400 $128,000
Q1 2021 May 17, 2021	BUY	$2.68 - $3.8 $87,636 - $124,260	32,700 New	32,700 $95,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.